New vaccine aims to shield against 24 pneumonia strains

NCT ID NCT07543198

Completed ⭐️ VACCINE ⭐️ Sponsor: Sinovac Life Sciences Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new 24-valent pneumococcal conjugate vaccine (PCV24) in 385 healthy adults aged 18 and older. The goal was to check its safety and how well it triggers an immune response compared to an existing vaccine. Participants received one dose of either a low, middle, or high dose of PCV24 or a standard vaccine, and were monitored for side effects and antibody levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 24-valent pneumococcal conjugate vaccine (PCV24)
What this could lead to: If successful, this vaccine could protect against more types of pneumococcal bacteria than current vaccines, reducing pneumonia and related infections.
What could go wrong: This is an early-phase trial with only 385 participants, so results may not apply to everyone. The vaccine may cause side effects or not work as well as expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PNEUMOCOCCAL INFECTIOUS DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pneumococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PNEUMOCOCCAL INFECTIOUS DISEASE

Contacts and locations

Locations

Shaanxi Provincial Center for Disease Control and Prevention

Xi'an, Shaanxi, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.